Name: 3rd European Congress on Vaccines and Immunology
Start: 2020-09-23
End: 2020-09-25
Location: London

- Quick Links -

Previous Conference Performers / Professionals From Around The Globe

Pierre A. Morgon

CEO & Founder, MRGN Advisors.
Switzerland

Matthias Giese

CEO & Founder, Institute for Molecular Vaccines
Germany

Maurizio Chiriva-Internati

Director of the Basic and Translational research Texas Tech University Health Sciences Center.
USA

Dennis Christensen

Senior Scientist Head of Vaccine Adjuvant Research , Infectious Disease Immunology Center for Vaccine Research Statens Serum Institut
Denmark

Akira Homma

Chairman Policy and Strategy Council, Bio-Manguinhos/Fiocruz Brazil
Brazil

Charles J. Arntzen

Arizona State University USA
USA

Emmanuel Drouet

Professor of Virology, University Grenoble-Alpes, France
France

Rene Labatut

Vice President Global Manufacturing Technology sanofi pasteur France
France

Giulio F. Tarro

President, Foundation T. & L. de Beaumont Bonelli for cancer research, Italy
Italy

Marek Malecki

President - Phoenix Biomolecular Engineering Foundation Principal Investigator at the National Institutes of Health University of Utrecht.
USA

Marc Paul Girard

Honorary Professor, Paris 7 Denis Diderot University Member of the French National Academy of Medicine and French Veterinary Academy, France
France

Giampietro Corradin

Group leader, University of Lausanne, Switzerland
Switzerland

Tracks & Key Topics

Tracks

Academic Key Topics

Business Key Topics

ABOUT CONFERENCE

Vaccines Committee cordially invites all the interested and enthusiastic participants across the globe to its prestigious "3^rd European Congress on Vaccines and Immunology" to be held during September 23-24, 2020 in London, UK. Which highlights the theme “Role of Vaccines in Immunization towards Covid19 and other Viral Diseases”.

The event will have Keynote speakers, Plenary speakers, Invited speakers, and fresh contributed speakers. Furthermore, a variety of poster presentations along with workshops and special sessions would be interested in listeners.

The aim of the Vaccines & Immunization 2020 is to promote quality research and real-world impact in an atmosphere of true international cooperation between scientists and engineers by bringing together again the world-class researchers, International Communities and Industrial heads to discuss the latest developments and innovations in the fields of Vaccines.

We sincerely hope that Vaccines conferences serve as an international platform for meeting researchers from around the world, widen professional interaction, and create new opportunities, including establishing new alliances.

We look forward to seeing you at Vaccines & Immunization 2020 in London, UK.

Why attend???

Vaccines & Immunization 2020 is aimed to give an opportunity that scholars from around the world focused on learning about Vaccines & Immunology and its advances; this is the best opportunity to reach the largest gathering of participants from the Vaccines & Immunology community. It provides an explicit platform for presentations that distributes information, meets with current and potential scientists. World-renowned speakers, the most recent techniques, developments, and the latest updates in Vaccines & Immunology are hallmarks of this conference.

Target Audience:

Researchers & Scientists related to Vaccines R&D
Deans and Professors
CEO / CSO / COO
CMO / Head of Scientific Affairs
Head of Virology
Head of Immunology
University Faculty
Medical Schools/Colleges
Nursing Schools/Colleges
Associations and Societies related to Vaccines R&D
Vaccination Programme Organising Government and Non-government Organisations
Business Entrepreneurs
Medical devises Manufacturing Companies
Vaccines Manufacturing Companies
Vaccines Developers and Investigators
Strategic Alliance
Alliance/Partnership Development
VP of Microbiology

SESSION/TRACKS

Track 1: Emerging and Re-Emerging Infectious Diseases

Emerging diseases are those whose incidence in humans has increased in the past two decades, and re-emergence is the reappearance of a known disease after a significant decline in incidence.4 The magnitude of the problem is illustrated by the appearance of several new pathogens causing disease of marked severity, such as the human immunodeficiency virus (HIV) and other retroviruses, arenaviruses, Hantaviruses and the Ebola virus. Old pathogens such as cholera, plague, dengue hemorrhagic fever and yellow fever have re-emerged and are having considerable impact in the Americas.

Re-emerging, or resurging, diseases are those that have been around for decades or centuries, but have come back in a different form or a different location. Examples are West Nile virus in the Western hemisphere, monkeypox in the United States, and dengue rebounding in Brazil and other parts of South America and working its way into the Caribbean.

HIV/AIDS
Malaria and Tuberculosis
Influenza
SARS
Ebola
Nipah
West Nile Virus
Monkey pox

Track 2: Vaccine Research & Development

Vaccine Development is an activity that focuses on a variety of technological initiatives and applied research, which enhance and promote improved systems and practices for vaccine safety. In the past year, the unprecedented Ebola disease outbreak galvanized research and industry response and as we continue to search for solutions, we must review the lessons learned in order to overcome the current challenges. Vaccines development is a long, complex process, often lasting 10-15 years and involving a combination of public and private involvement. The current system for developing, testing, and regulating vaccines developed during the 20th century as the groups involved standardized their procedures and regulations.

Basic Vaccinology
Vaccines discovery, development & formulation
Vaccine Management & Quality Assurance
Vaccine Immunoinformatics

Track 3: Influenza and Respiratory Diseases

Population protection by vaccination against infections has been one of the major achievements of public health and is of considerable importance in controlling respiratory diseases.

Vaccine against the Influenza Virus
Vaccine against Pertussis
Vaccine against Tuberculosis
Vaccine against Streptococcus Pneumonia

Track 4: Vaccines Bioprocessing and Manufacturing

The vaccine industry, particularly, in major Western markets, continues to be dominated by a few major, long-established players that primarily manufacture aging, long-marketed, non-recombinant (nongenetically engineered) vaccines. The industry, however, will be changing in the coming years and this change may come rather rapidly.

Track 5: Vaccines Pre-Clinical Validation to Clinical Trials

Assess how to improve your clinical trial performance, from developing novel immunological assays to creating clinical efficacy.

Track 6: Anti-Microbial Resistance

Antimicrobial resistance (AMR) is one of the biggest threats to both human and animal health today. AMR can affect anyone, of any age, and in any country. It can lead to longer hospital stays, higher medical costs, and possibly death.

AMR occurs when germs that can cause infections, such as bad bacteria, become resistant to medicines, such as antibiotics, used to kill them.

There is a growing appreciation for the role of vaccines in confronting the problem of antimicrobial resistance. Vaccines can reduce the prevalence of resistance by reducing the need for antimicrobial use and can reduce its impact by reducing the total number of cases.

Role of Vaccines in Combating Antibioticâ€Resistant Bacteria

Vaccines as part of antibiotic stewardship
Prevent bacterial infections and avoid need for antibiotics
Prevent use of antibiotics for viral infections
Reduce transmission of antibioticâ€resistant strains
Develop new vaccines to target resistant pathogens
Assess regulatory pathways and clinical trial designs to facilitate vaccine development
Understand vaccine markets and incentives to support R&D for new vaccines

Track 7: Vaccines Technology

Increasing and evolving demands for all types of products creates new challenges for vaccine manufacturers. As the market grows, innovative approaches to development and production will be needed to accelerate the delivery of novel products.

Health policy-makers are encouraging the use of new technology to meet these challenges and make vaccines more accessible.

DNA delivery technologies
Needle-free vaccine delivery
Nanopatch Technologies
Delivery systems for prophylactic and therapeutic vaccines

Track 8: Cancer and Immunotherapy

Immunotherapeutics is a treatment that uses your body's immune system to help fight cancer. Get information about the different types of immunotherapy and the types of cancer they are used to treat. The main types of immunotherapy now being used to treat cancer include:

Cancer vaccines
Monoclonal antibodies
Immune checkpoint inhibitors
Other, non-specific immunotherapies

Some types of immunotherapy are also sometimes called biologic therapy or biotherapy.

In the last few decades immunotherapy has become an important part of treating some types of cancer. Newer types of immune treatments are now being studied, and they’ll impact how we treat cancer in the future.

Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way. Others help train the immune system to attack cancer cells specifically. Immunotherapy works better for some types of cancer than for others. It’s used by itself for some of these cancers, but for others it seems to work better when used with other types of treatment.

Feline Leukemia Vaccines
Cancer Immunotherapy Biomarkers
Non-specific cancer immunotherapies and adjuvants
Oncolytic viral therapies
Gene-therapy
CAR T-Cell Therapy

Track 9: Vaccines Safety and Efficacy

Vaccines are the best defense we have against serious, preventable and sometimes deadly contagious diseases. Vaccines are some of the safest medical products available, but like any other medical product, there may be health risks. Accurate information about the value of vaccines as well as their possible side-effects helps people to make informed decisions about vaccination. The safety of vaccines is carefully monitored, starting early in the product development and continuing for as long as the vaccine is being used. Find out about what is done before and after vaccines are approved for use and what is known about the benefits and safety of specific vaccines. There is a lot of false information about vaccines safety on the Internet. This can be confusing. Discover the answers to common questions and concerns about vaccines.

Vaccine Administration, Storage & Handling
Factors Influencing Vaccine efficacy
Vaccine safety communication
Vaccine Safety Monitoring and Vaccine Pharmacovigilance
Patient and Public acceptance and perceptions
Post marketing surveillance of Vaccines

Track 10: Veterinary Vaccines

Veterinary vaccines are to improve the health and welfare of companion animals, cost-effectively increase the production of livestock, and prevent animal-to-human transmission from both domestic animals and wildlife. Several vaccine types can de be distinguished among the second-generation veterinary vaccines, depending on whether they are live or inactivated, according to the strain of rabies virus used and the characteristics of the cell-substrate chosen for viral replication. More recently a third generation of live veterinary rabies vaccine has been developed using recombinant technology. Depending upon the expression system these vaccines are used either parenterally or orally. Oral rabies vaccines are widely used in foxes in Europe and raccoons in the USA.

Current status of Veterinary Vaccines
Safety or efficacy of a Veterinary medicine
Vaccines for Livestock Diseases
Animal health outcomes
Recent Advances in Animal Vaccination

Track 11: Hepatitis Vaccines

Viral hepatitis is a genuine medical issue everywhere throughout the world. Notwithstanding, the decrease of the bleakness and mortality because of immunizations against hepatitis A and hepatitis B has been a noteworthy segment in the general lessening in antibody preventable infections. We will examine the study of disease transmission, immunization advancement, and post-inoculation impacts of the hepatitis A and B infection. Furthermore, we examine endeavors to give the hepatitis D antibody to the 350 million people tainted with hepatitis B all around. Given the absence of a hepatitis C antibody, the numerous difficulties confronting the generation of a hepatitis C immunization will be appeared, alongside present and previous inoculation trials. As there is no present FDA-endorsed hepatitis E immunization, we will introduce inoculation information that is accessible in whatever is left of the world. At last, we will talk about the current difficulties and inquiries confronting future undertakings for every one of the hepatitis infections, with endeavors proceeding to center on significantly diminishing the dismalness and mortality related to these genuine contaminations of the liver.

Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D

Track 12: HIV/AIDS Vaccines

The long-term aim is to develop a non-toxic and effective vaccine that defends people worldwide after getting infected with HIV. However, even if a vaccine only defends some people who get vaccinated, or even if it affords less than total protection by reducing the threat of infection, it could still have a major impact on the rates of transmission and help control the pandemic, particularly for populations at high risk of HIV infection. A partially effective vaccine could decrease the number of people who get infected with HIV, further reducing the number of people who can pass the virus on to others. By considerably reducing the number of new-fangled infections, we can stop the widespread.

HIV Vaccine Strategies
T cell-based Vaccines
B cell-based Vaccines
Innate & Mucosal Immunity
Viral Vaccine Vectors

Track 13: Preventable Disease Vaccines

An antibody preventable sickness is an irresistible malady for which a compelling preventive immunization exists. On the off chance that a man procures an immunization-preventable ailment and passes on from it, the demise is viewed as an antibody preventable passing.

Diphtheria
Haemophilus influenzae serotype b disease
Meningitis
Tuberculosis
Yellow fever
Mumps
Measles

MARKET ANALYSIS

Vaccines Conferences advisory board invites all the participants across the world to attend “3rd European Congress on Vaccines & Immunology” going to be held during Sep 23-24, 2020 in London, UK. The Theme of the conference is "Role of Vaccines in Immunization towards CoVid-19 and other Viral Diseases" will explore the advances in Vaccines and Immunology.

Importance & Scope:

This conference could be an exceptional event that brings along a novel and International mixture of huge and medium cognizance on Vaccines and Therapeutics, leading universities engendering the conference an ideal platform to apportion expertise, foster collaborations across trade and world, and assess elevating technologies across the world.

Vaccination is a key to eradicate the diseases. It is a subject for the professionals who looks beyond the clinical prospects. Traditional approaches to vaccine design were to emasculate or inactivate the human pathogen or a cognate animal homologue, Vaccinology is the science of vaccine development and how the immune system responds to vaccines, but additionally includes perpetual evaluation of immunization programs and vaccine safety and efficacy, as well as surveillance of the epidemiology of vaccine-preventable diseases. This chapter provides a brief overview of some of the main concepts of immunology and Vaccinology as they relate to immunization. Vaccines & Immunization 2020 amasses all the extroverts under one roof of current advances.

Market Growth of Vaccine Research in the last and upcoming ten years

The global vaccines market is one of the fastest-growing segments and new predictions estimate the value of the market to reach between $48 billion and more than $70 billion over the next five to eight years.

According to a new report released by Transparency Market Research, the value of the global human vaccines market is expected to grow from $28.3 billion in 2015 to $72.5 billion in 2024. The projection would represent a compound annual growth rate (CAGR) of 11.2% from 2016 to 2024. Even though the dollar figure is large and growing, vaccines still only account for 3% of the market share within the global pharmaceutical industry. The report broke down expectations by segments. By age group, paediatric vaccines accounted for 57.5% of the share in 2015, but adult vaccines are expected to grow at a 13.2% CAGR during the forecast period. When the research group analysed the market by product, they found the pneumococcal segment to have the majority share in 2015, but expect hepatitis products to demonstrate strong growth through 2024. By vaccine type, the conjugate vaccines held the majority share in 2015, but the combination vaccines were expected to have the largest CAGR.